A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
A phase 1/2 trial of QLC5508, Abiraterone acetate, Enzalutamide in prostate cancer, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer is a phase 1/2 interventional study registered as NCT07198633 by Qilu Pharmaceutical Co., Ltd., with 212 participants planned, started 2025-11-05 and due to reach its primary completion in 2026-12. Interventions recorded: QLC5508, abiraterone acetate, enzalutamide, QLH12016. Conditions listed: Advanced Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares QLC5508, Qilu Pharmaceutical.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares QLC5508, Qilu Pharmaceutical.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares QLC5508, Qilu Pharmaceutical.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialAbiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.